Results 101 to 110 of about 113,188 (264)

Peripheral Blood DNA Methylation Changes Precede Lymphoma Diagnosis in Primary Sjögren's Disease

Arthritis &Rheumatology, EarlyView.
Objective Primary Sjögren's disease (SjD) is a systemic autoimmune disease associated with an increased risk of lymphoma. The molecular mechanisms underlying lymphomagenesis remain poorly understood, and sensitive biomarkers for early identification of patients at high risk of developing lymphoma are lacking.
Hanna Lidberg, Cecilia Fugmann, Juliana Imgenberg‐Kreuz   +2 more
wiley   +1 more source

Age‐associated B cells contribute to inflammation via antibody‐independent mechanisms in Takayasu's arteritis

Arthritis &Rheumatology, Accepted Article.
Objective Although Takayasu's arteritis (TAK) is not a prototypical autoantibody‐mediated disease, accumulating evidence suggests that B cells are involved. This study aimed to investigate the pathway of B‐cell activation and its contributions to TAK pathogenesis.
Chenglong Fang, Xiaoxi Yang, Xiaochuan Sun, Shangyi Jin, Lihong Du, Jinwei Gao, Jing Li, Zhen Chen, Yuexin Chen, Mengtao Li, Xinping Tian   +10 more
wiley   +1 more source

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

British Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis, Leiah J. Brigitha, Lidwien M. Hanff, Alwin D. R. Huitema, Inge M. van der Sluis, Meta H. M. Diekstra   +5 more
wiley   +1 more source

Impact of measurable residual disease in combination with CD19 on postremission therapy choices for adult t(8;21) acute myeloid leukemia in first complete remission

Cancer Medicine
Background The post‐remission therapy (PRT) choices for adult t(8;21) acute myeloid leukemia (AML) in first complete remission (CR1) need to be further explored.
Xi Jia, Naying Liao, Sijian Yu, Huan Li, Hui Liu, Haiyan Zhang, Jun Xu, Yunqian Yao, Han He, Guopan Yu, Qifa Liu, Yu Zhang, Pengcheng Shi   +12 more
doaj   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Blinatumomab bridges the gap between leukemia and immunity

OncoImmunology, 2017
Takahiro Yamazaki, Lorenzo Galluzzi
doaj   +1 more source

Fouling‐Free Inertial Microfluidic Cell Clarification for Lentivirus Manufacturing

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Lentiviral vectors (LVVs) are widely used as gene‐delivery vehicles in cell and gene therapy, enabling stable integration of transgenes into target cells. However, efficient clarification of LVV harvest remains a major bottleneck in large‐scale manufacturing, as conventional depth filtration often results in significant product loss.
Dohyun Park, Alexander Bevacqua, Mingyang Cui, Marina Nichols, Jianzhu Chen, Jongyoon Han   +5 more
wiley   +1 more source

Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development

Clinical Pharmacology &Therapeutics, EarlyView.
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu, Qingqing Xiao, Lixuan Qian, Siyuan Sun, Zhu Zhou, Michael Z. Liao, Chunze Li   +6 more
wiley   +1 more source

Model‐Based Analysis with Mechanistic Insights to CAR‐T‐Cell Therapy Kinetics: Case Study with Axicabtagene Ciloleucel and Brexucabtagene Autoleucel

Clinical Pharmacology &Therapeutics, EarlyView.
Model‐informed drug development is increasingly used to support chimeric antigen receptor (CAR)‐T‐cell therapy programs. However, most population pharmacokinetic (PK) CAR‐T‐cell models available in literature are variations of an empirical piecewise‐linear model, which accurately describes the observed data but lacks a mechanistic foundation.
Anna M. Mc Laughlin, Martin Bergstrand, Ana Ruiz‐Garcia, Simone Filosto, Rhine Shen   +4 more
wiley   +1 more source

Characterization of the Immune Response after Oral Cholera Vaccination (OCV) and Effects of Mycophenolate Mofetil on Priming of this Immune Response—A Randomized, Placebo‐Controlled Trial

Clinical Pharmacology &Therapeutics, EarlyView.
Mycophenolate mofetil (MMF) is an immunosuppressive drug widely used by solid organ transplant recipients. Although it is known that MMF suppresses immune responses, its exact effects on specific vaccinations have not been investigated yet. Mucosal vaccinations are increasingly used, such as a cholera vaccination consisting of two oral immunizations ...
Boukje C. Eveleens Maarse, Aliede E. in 't Veld, Hendrika W. Grievink, Manon A.A. Jansen, Matthijs Moerland   +4 more
wiley   +1 more source